研究

Ohta R, Tanaka K, Miyata M, Tanizaki J, Hayashi H.

Diagnostic and Therapeutic Challenges in an Older Patient With Concurrent Small-Cell Lung Carcinoma and Primary Duodenal Adenocarcinoma: A Case Report

Ohta R, Tanaka K, Miyata M, Tanizaki J, Hayashi H.

Peritoneal Metastasis Mimicking Chemotherapy-Induced Complications in Lung Adenocarcinoma: A Diagnostic Challenge of a Case Report

Boku S, Satake H, Mitani S, Maeda K, Kudo T, Yamaguchi T, Takagi T, Kawakami H.

A placebo-controlled study of the doses and efficacy of Lentinula edodes mycelia for oxaliplatin-induced peripheral neuropathy in colorectal cancer

Wakabayashi M, Taniguchi H, Makiyama A, Sunakawa Y, Takeda H, Arimizu K, Okumura Y, Inagaki C, Mitani S, Kudo T, Yuki S, Akazawa N, Kudo C, Mori K, Matsuda T, Muro K.

A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study)

Zenke Y, Niho S, Toi Y, Yamaguchi M, Hara S, Akazawa Y, Hosomi Y, Yonesaka K, Akamatsu H, Yokoyama T, Tanizaki J, Ueno K, Gyotoku H, Misumi T, Nakagawa K, Yamamoto N, Tsuboi M.

Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study

Kawanaka Y, Inagaki C, Okura M, Mitani S, Takahama T, Yonesaka K, Chiba Y, Nakagawa K, Kawakami H, Hayashi H.

Prognostic impact of gene alterations via homologous recombination DNA repair gene alteration status in pancreatic ductal adenocarcinoma

Ohta R, Yamamoto N, Tanaka K, Sano C, Hayashi H.

Clinical Characteristics and Outcomes of SMARCA4-Mutated or Deficient Malignancies: A Systematic Review of Case Reports and Series

Shiraishi N, Takahama T, Sakai K, Tanaka K, Nakagawa Y, Kanemura H, Nakayama T, Kawanaka Y, Kurosaki T, Suzuki S, Iwasa T, Tanizaki J, Inagaki C, Yonesaka K, Fukuoka K, Mitsudomi T, Nishio K, Hayashi H, Nakagawa K.

Detection of Overlooked Rare EGFR Mutations in Non-small Cell Lung Cancer Using Multigene Testing.

Fujita Y, Matsuoka H, Chiba Y, Tsurutani J, Yoshida T, Sakai K, Nakura M, Sakamoto R, Makimura C, Ohtake Y, Tanaka K, Hayashi H, Takahama T, Tanizaki J, Koyama A, Nishio K, Nakagawa K.

Dual single‑nucleotide polymorphism biomarker combination for opioid selection to treat cancer pain.

Furugaki K, Fujimura T, Sakaguchi N, Watanabe Y, Uchibori K, Miyauchi E, Hayashi H, Katayama R, Yoshiura S.

Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK-inhibitor-induced tolerant persister cells in ALK-fusion-positive lung cancer

Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K, Hayashi H, Sakai K, Enatsu S, Frimodt-Møller B, Matsui T, Varughese SC, Carlsen M, Visseren-Grul C, Nakagawa K.

Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset

Ikeda H, Kawase K, Nishi T, Watanabe T, Takenaga K, Inozume T, Ishino T, Aki S, Lin J, Kawashima S, Nagasaki J, Ueda Y, Suzuki S, Makinoshima H, Itami M, Nakamura Y, Tatsumi Y, Suenaga Y, Morinaga T, Honobe-Tabuchi A, Ohnuma T, Kawamura T, Umeda Y, Nakamura Y, Kiniwa Y, Ichihara E, Hayashi H, Ikeda JI, Hanazawa T, Toyooka S, Mano H, Suzuki T, Osawa T, Kawazu M, Togashi Y.

Immune evasion through mitochondrial transfer in the tumour microenvironment

Yasuda K, Kiyota N, Matsuura K, Saito S, Honma Y, Imamura Y, Tanaka K, Zenda S, Onoe T, Kodaira T, Kobayashi S, Aoyama H, Hanai N, Homma A.

Indications for chemoradiotherapy in older patients with locally advanced head and neck cancer in Japan: a questionnaire survey in the JCOG head and neck cancer study group.

Sakai H, Tsurutani J, Ozaki Y, Ishiguro H, Nozawa K, Yamanaka T, Aogi K, Matsumoto K, Iwasa T, Tokiwa M, Tsuneizumi M, Miyoshi Y, Kitagawa C, Yamamoto M, Takano Y, Imamura CK, Chiba Y, Takiguchi D, Ezumi T, Takano T.

A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)

Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, Vicente Baz D, Sugawara S, Cobo M, Pérol M, Mascaux C, Poddubskaya E, Kitazono S, Hayashi H, Hong MH, Felip E, Hall R, Juan-Vidal O, Brungs D, Lu S, Garassino M, Chargualaf M, Zhang Y, Howarth P, Uema D, Lisberg A, Sands J; TROPION-Lung01 Trial Investigators.

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Matsubara Y, Masuishi T, Hosoda W, Hirano H, Mishima S, Takahashi H, Otsuka T, Kawasaki K, Kawakami T, Yanagihara K, Shimura T, Komoda M, Murayama K, Minashi K, Yamamoto Y, Shinohara Y, Nishina S, Musha N, Kato K, Kawakami K, Shinozaki K, Tsuchihashi K, Ando T, Kito Y, Makiyama A, Mitani S, Hino K, Izawa N, Oze I, Muro K.

Ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum-based chemotherapy: A multicenter observational retrospective study (WJOG13420G)

Watanabe S, Haratani K, Nakayama T, Takahama T, Iwasa T, Takeda M, Hayashi H

Clinical and molecular landscape of metastatic extramammary Paget's disease

Takakura T, Iwasa T, Imamura CK, Watanabe S, Hayashi H.

Pharmacokinetics, efficacy and safety of palbociclib and fulvestrant in a patient with hormone receptor-positive, human epidermal growth factor receptor 2 negative metastatic breast cancer with end-stage renal disease undergoing hemodialysis: A case report

Jänne PA, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D, Ahn MJ, Smit E, Johannes de Langen A, Pérol M, Pons-Tostivint E, Novello S, Hayashi H, Shimizu J, Kim DW, Pereira K, Cheng FC, Taguchi A, Cheng Y, Dunton K, Ali A, Goto K.

Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC

Lee SH, Lu S, Hayashi H, Felip E, Spira AI, Girard N, Kim YJ, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Dias JM, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Chih-Hsin Yang J, Besse B, Thomas M, Shah S, Baig M, Curtin JC, Zhang J, Xie J, Sun T, Sethi S, Wang M, Fennema E, Daksh M, Ennis M, Bauml JM, Cho BC.

Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA

Miyata M, Hayashi H

Current treatment landscape for patients with non-small cell lung cancer with common EGFR mutations

Wu YL, Kim HR, Soo RA, Zhou Q, Akamatsu H, Chang GC, Chiu CH, Hayashi H, Kim SW, Goto Y, Kato T, Zhou J, Lee VH, Nishio M, Han B, Kim DW, Lu S, Polli A, Martini JF, Toffalorio F, Wong CH, Mok T.

First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study

Hakozaki T, Tanaka K, Shiraishi Y, Sekino Y, Mitome N, Okuma Y, Aiba T, Utsumi T, Tanizaki J, Azuma K, Hara S, Morita R, Niho S, Yokoyama T, Toyozawa R, Horinouchi H, Okamoto I, Hosomi Y, Ohe Y.

Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON)

Kodama H, Narita Y, Nakamura M, Takahashi M, Mizukami T, Ando T, Mitani S, Komori A, Hosokawa A, Moriwaki T, Sugiyama K, Taguri M, Orihara S, Kagamu H, Yamaguchi T, Nishikawa H, Muro K.

A multicenter, prospective, observational study of nivolumab readministration for advanced gastric cancer (NIVO RETURNS)

Ahn MJ, Lisberg A, Goto Y, Sands J, Hong MH, Paz-Ares L, Pons-Tostivint E, Pérol M, Felip E, Sugawara S, Hayashi H, Cho BC, Blumenschein G Jr, Shum E, Lee JS, Heist RS, Cornelissen R, Chang WC, Kowalski D, Zebger-Gong H, Chargualaf M, Gu W, Lan L, Howarth P, Joseph R, Okamoto I.

A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC

Fujita Y, De Velasco MA, Hayashi H, Nakagawa K, Nishio K.

Exploration of genes related to the development of cancer of unknown primary

Cho BC, Hayashi H, Lee JS, Lee SH, Danchaivijitr P, Cheng Y, Liu B, Alip A, Xiong H, How SH, Chang GC, Yang JC, Yoshioka H, Nahit Şendur MA, Prabhash K, Azuma K, Lee YG, Lin CC, Matsumoto S, Sunpaweravong P, Xia Y, Martinez M, Bauml JM, Sethi S, Lu S.

Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset

Elez E, Yoshino T, Shen L, Lonardi S, Van Cutsem E, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Morris VK, Wu C, Usari T, Laliberte R, Dychter SS, Zhang X, Tabernero J, Kopetz S; BREAKWATER Trial Investigators.

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer

Takagi K, Saito G, Tanaka H, Kubo S, Shukuya T, Tsugitomi R, Sasaki T, Oba T, Mamesaya N, Yamanaka T, Tachihara M, Gyotoku H, Nagashima H, Tamiya M, Kanemura H, Tozuka T, Furuta M, Sakata S, Mouri A, Miwa H, Kawachi H, Ninomiya T, Nagai Y, Ogino H, Ito K, Tamura Y, Tokito T, Ishihara M, Ashinuma H, Tsukita Y, Kogure Y, Masuda T and Suzuki T.

Lenvatinib for Patients with Previously Treated Advanced Thymic Carcinoma in Real-world Settings.

Komori A, Hironaka S, Kadowaki S, Mitani S, Furuta M, Kawakami T, Makiyama A, Takegawa N, Sugiyama K, Hirano H, Ando T, Matsushima T, Chida A, Kashiwada T, Komoda M, Matsumoto T, Oda H, Yabusaki H, Kawakami H, Yamazaki K, Boku N, Hyodo I, Yoshimura K, Muro K; West Japan Oncology Group (WJOG).

Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS

Shiraishi K, Okada M, Yamamoto S, Matsubara Y, Masuishi T, Shimozaki K, Yamamoto Y, Hirose S, Sugiyama K, Furuta M, Machida N, Takahashi N, Yoshii T, Kito Y, Tsuzuki T, Boku S, Tsuchihashi K, Sugaya A, Takayama T, Komori A, Mitani S, Matsumoto T, Nishimura T, Hirata K.

The efficacy and safety of FOLFOX therapy for advanced esophageal squamous cell carcinoma

Yonesaka K, Kurosaki T, Tanizaki J, Kawakami H, Tanaka K, Maenishi O, Takamura S, Sakai K, Chiba Y, Teramura T, Goto H, Otsuka E, Okida H, Funabashi M, Hashimoto Y, Hirotani K, Kamai Y, Kagari T, Nishio K, Kakimi K, Hayashi H.

Chromosomal Instability Is Associated with cGAS-STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer.

Shukuya T, Asao T, Goto Y, Mimori T, Takayama K, Kaira K, Tanaka H, Ko R, Amano Y, Tachihara M, Suzuki T, Tanizaki J, Sugawara S, Zenke Y, Shirai Y, Hayashi T, Mori K, Takahashi K.

Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial

Paz-Ares LG, Juan-Vidal O, Mountzios GS, Felip E, Reinmuth N, de Marinis F, Girard N, Patel VM, Takahama T, Owen SP, Reznick DM, Badin FB, Cicin I, Mekan S, Patel R, Zhang E, Karumanchi D, Garassino MC.

Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer.

Mochizuki S, Ohta R, Konya Y, Isomoto K, Takahama T, Tanizaki J, Hayashi H.

Paraneoplastic Syndromes Mimicking Dermatomyositis and Remitting Seronegative Symmetrical Synovitis With Pitting Edema (RS3PE) Syndrome in Cancer of Unknown Primary Origin: A Case Report

Ninomiya T, Kemmotsu N, Mukohara F, Magari M, Miyamoto A, Ueda Y, Ishino T, Nagasaki J, Fujiwara T, Yamamoto H, Hayashi H, Tachibana K, Ishida J, Otani Y, Tanaka S, Toyooka S, Okamoto I, Togashi Y.

Myeloid Cells Induce Infiltration and Activation of B Cells and CD4+ T Follicular Helper Cells to Sensitize Brain Metastases to Combination Immunotherapy

Felip E, Cho BC, Lu S, Şendur MAN, Gadgeel SM, Sethi S, Bauml JM, Hayashi H.

Plain language summary of first-line amivantamab-lazertinib in previously untreated high-risk EGFR-altered non-small-cell lung cancer in MARIPOSA

Shiraishi Y, Shimose T, Tobino K, Toi Y, Wakuda K, Matsumoto H, Sakaguchi T, Mashimoto A, Hayashi H, Ebina-Shibuya R, Mori M, Taniguchi Y, Kuyama S, Kashiwabara K, Furuyama K, Yoshimine K, Kimura Y, Kobayashi H, Kishimoto J, Okamoto I.

Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002)

Kadowaki S, Otsuka T, Minashi K, Nishina S, Yabusaki H, Inagaki C, Nishina T, Yasui H, Matsuoka H, Machida N, Tsuda M, Nagashima F, Hosaka H, Matsubara J, Arai H, Ida S, Kimijima Y, Matsuda Y, Muto M, Muro K.

An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study

Murata D, Hayashi H

Dual Targets, Two Paths: Amivantamab: A Promising Treatment for NSCLC With Exon 14 Skipping Mutations of MET

Kurosaki T, Kanemura H, Otani T, Kawanaka Y, Fukuda Y, Kudo K, Tanizaki J, Suzuki S, Tomida S, Sakai K, Chiba Y, Ito A, Nishio K, Nakagawa K, Hayashi H.

Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancer.

Yang JC, Lu S, Hayashi H, Felip E, Spira AI, Girard N, Kim YJ, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourão Dias J, Besse B, Passaro A, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yoshioka H, Thomas M, Nguyen D, Ou SI, Mukhedkar S, Prabhash K, D'Arcangelo M, Alatorre-Alexander J, Vázquez Limón JC, Alves S, Stroyakovskiy D, Peregudova M, Şendur MAN, Yazici O, Califano R, Gutiérrez Calderón V, de Marinis F, Kim SW, Gadgeel SM, Owen S, Xie J, Sun T, Mehta J, Venkatasubramanian R, Ennis M, Fennema E, Daksh M, Roshak A, Man J, Knoblauch RE, Bauml JM, Baig M, Shah S, Sethi S, Cho BC; MARIPOSA Investigators.

Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC

Kitazono S, Ono A, Kawamura T, Hataji O, Tanaka H, Matsumoto S, Watanabe N, Nagashima H, Oki M, Takahashi M, Anazawa T, Shirai T, Yamashita A, Wortman-Vayn H, Bhattacharya A, Agrawal T, Baig M, Knoblauch RE, Hayashi H.

Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC

Steuer CE, Hayashi H, Su WC, Nishio M, Johnson ML, Kim DW, Massarelli E, Felip E, Gold KA, Murakami H, Baik CS, Kim SW, Smit EF, Fujimura M, Fan PD, Truchon K, Su X, Sternberg DW, Jänne PA.

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy